Chargement de la fiche…
Chargement de la fiche…
rhumatologie
Praticien hospitalier
Bordeaux (33076)
Systemic Sclerosis and Related Diseases · Rheumatoid Arthritis Research and Therapies · Systemic Lupus Erythematosus Research
Tout est calculé à partir des sources publiques (RPPS, PubMed, OpenAlex, OpenStreetMap…) — aucun classement éditorial.
2012–2026
Centre National de la Recherche Scientifique
2012–2026
Université de Bordeaux
2023–2025
Sciences Po Bordeaux
2012–2025
Centre Hospitalier Universitaire de Bordeaux
2022
Hospital General Universitario Gregorio Marañón
2021
Inserm
0
h-index
0
i10
0
citations
Le h-index mesure la productivité scientifique : ce médecin a publié 45 articles cités au moins 45fois par d'autres chercheurs. Plus c'est élevé, plus son travail influence la communauté médicale.
Côté patient
Comprendre votre pathologie, exercices à domicile, applications validées, paramédicaux à proximité — gratuit, sans inscription.
DES Rhumatologie · Rhumatologie (SM) — Diplôme d'Études Spécialisées
DE Docteur en médecine — Capacité / Certificat d'Études Spéciales
0
travaux
0
h-index
0
i10-index
0
citations
2026Current opinion in rheumatology
PubMed ↗What have we learned about systemic sclerosis from the EUSTAR database?
2026Rheumatology (Oxford, England)
PubMed ↗Clinical characteristics and risk factors for calcinosis cutis in systemic sclerosis: insights from the EUSTAR database
2026BMC women's health
PubMed ↗Cervical cancer screening practices among patients with autoimmune and inflammatory rheumatic diseases: a descriptive cross-sectional observational study
2026Annals of the rheumatic diseases
PubMed ↗Risk score for early mortality to stratify for intensive SSc therapy in the EUSTAR network: the RESIST score
2026Microvascular research
PubMed ↗Nailfold video capillaroscopy predicts severe progression at three years in systemic sclerosis: Results from SCLEROCAP study
2026Joint bone spine
PubMed ↗Club Rhumatismes et Inflammation guidelines for anti-interleukin-1 therapy: 2026 update
2025The Lancet. Rheumatology
PubMed ↗Exploiting a unified vascular framework to predict organ-specific complications and accomplish disease modification in systemic sclerosis
2025Rheumatology (Oxford, England)
PubMed ↗Gastroesophageal reflux disease is associated with a more severe interstitial lung disease in systemic sclerosis in the EUSTAR cohort
2025Joint bone spine
PubMed ↗French recommendations for assessing and managing the risk of cancer before the initiation of targeted therapies for chronic rheumatic inflammatory diseases
2025Rheumatology (Oxford, England)
PubMed ↗Temporal trends in vascular medication use in 8079 patients with systemic sclerosis: insights to inform future trials and therapeutic strategies from the EUSTAR cohort
2025NPJ digital medicine
PubMed ↗Deep hierarchical subtyping of multi-organ systemic sclerosis trajectories - a EUSTAR study
2025La Revue de medecine interne
PubMed ↗[Between the normal and the pathological: The concept of pre-disease applied to systemic autoimmune rheumatic diseases]
2025The Journal of experimental medicine
PubMed ↗Altered X-chromosome inactivation of the TLR7/8 locus and heterogeneity of pDCs in systemic sclerosis
2025Autoimmunity reviews
PubMed ↗Crystalline silica on the lung-environment interface: Impact on immunity, epithelial cells, and therapeutic perspectives for autoimmunity
2025Rheumatology (Oxford, England)
PubMed ↗A comparative analysis of risk stratification tools in SSc-associated pulmonary arterial hypertension: a EUSTAR analysis
2025Joint bone spine
PubMed ↗Resolution of immune checkpoint inhibitors-induced inflammatory arthritis while maintaining active treatment with checkpoint inhibitors and after its discontinuation: An observational study
2024Rheumatology (Oxford, England)
PubMed ↗Occupational quantitative exposure to crystalline silica, solvents and pesticides and risk of clinical forms of systemic sclerosis
2024Arthritis research & therapy
PubMed ↗Does regression of skin thickening predict improvement of internal organ involvement and survival in patients with diffuse cutaneous systemic sclerosis? A EUSTAR analysis
2024Nature communications
PubMed ↗Inflammasome-targeted therapy might prevent adverse perinatal outcomes of recurrent chronic intervillositis of unknown etiology
2024RMD open
PubMed ↗Concordance and agreement between different activity scores in polymyalgia rheumatica
2024RMD open
PubMed ↗History of pre-eclampsia does not appear to be a risk factor for vascular phenotype in women with systemic sclerosis
2024Arthritis care & research
PubMed ↗Does the Impact of COVID-19 on Patients With Systemic Sclerosis Change Over Time?
2024European journal of immunology
PubMed ↗The deficiency of DNASE1L3 does not affect systemic sclerosis pathogenesis in two inducible murine models of the disease
2024RMD open
PubMed ↗Impact of autoantibody status on stratifying the risk of organ involvement and mortality in SSc: experience from a multicentre French cohort of 1605 patients
2024Journal of the European Academy of Dermatology and Venereology : JEADV
PubMed ↗Demographic and clinical characteristics of patients with coexistence of systemic sclerosis and atopy: A cross-sectional study
2024Chest
PubMed ↗Diffusing Capacity of the Lungs for Carbon Monoxide and Echocardiographic Parameters in Identifying Mild Pulmonary Hypertension in the EUSTAR Cohort of Patients With Systemic Sclerosis
2023RMD open
PubMed ↗Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study
2026Arthritis & rheumatology (Hoboken, N.J.)
PubMed ↗Impact of Evolving Treatment Patterns on Interstitial Lung Disease Progression in Systemic Sclerosis Using the European Scleroderma Trials and Research Database
2026Therapeutic advances in musculoskeletal disease
PubMed ↗The clinical phenotype of anti-Th/To+ patients in systemic sclerosis: a case-control study within the European Scleroderma Trials and Research cohort
2025Journal of scleroderma and related disorders
PubMed ↗Longitudinal association between nailfold capillaroscopy and incident interstitial lung disease: A EUSTAR database analysis
2025Arthritis care & research
PubMed ↗Oral Glucocorticoids for Skin Fibrosis in Early Diffuse Systemic Sclerosis: A Target Trial Emulation Study From the European Scleroderma Trials and Research Group Database
2025Journal of the American Heart Association
PubMed ↗Evaluation of Systemic Sclerosis Primary Heart Involvement and Chronic Heart Failure in the European Scleroderma Trials and Research Cohort
2023The Lancet. Rheumatology
PubMed ↗Beyond very early systemic sclerosis: deciphering pre‑scleroderma and its trajectories to open new avenues for preventive medicine
2026RMD open
PubMed ↗Safety and effectiveness of tocilizumab in systemic sclerosis: a multicentre French-Italian study
2025Arthritis & rheumatology (Hoboken, N.J.)
PubMed ↗Maintenance of Remission After Tocilizumab Withdrawal in Patients With Glucocorticoid-Dependent Polymyalgia Rheumatica
2025BMJ open
PubMed ↗Abatacept versus tocilizumab for the treatment of rheumatoid arthritis in TNF inhibitor inadequate responders: study protocol of the SUNSTAR randomised controlled open-label superiority trial
2025Annals of the rheumatic diseases
PubMed ↗Post hoc comparison of the effectiveness of tocilizumab, rituximab, mycophenolate mofetil, and cyclophosphamide in patients with SSc-ILD from the EUSTAR database
2026BMC rheumatology
PubMed ↗Prevalence of effective contraceptive use among patients with rheumatic diseases: a descriptive study
2025Journal of autoimmunity
PubMed ↗Total lung capacity is predictive of disease severity and survival in systemic sclerosis: A longitudinal analysis in 2347 patients from the French National Cohort Study
2025RMD open
PubMed ↗Evaluation of rheumatoid arthritis-associated interstitial lung disease in patients treated with JAK inhibitors: a MAJIK-SFR cohort study
2024Rheumatology (Oxford, England)
PubMed ↗Evolution of monoclonal gammopathy of undetermined significance in patients treated with JAK inhibitors for rheumatic diseases: data from the MAJIK-SFR registry
2024Rheumatology (Oxford, England)
PubMed ↗Biomarker analysis from the phase 2b randomized placebo-controlled trial of riociguat in early diffuse cutaneous systemic sclerosis
2023The Lancet. Rheumatology
PubMed ↗Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): open-label, long-term extension of a phase 2b, randomised, placebo-controlled trial
2026Joint bone spine
PubMed ↗Impact of regulatory events on JAK inhibitor prescribing in rheumatoid arthritis: Insights from the French MAJIK Registry
2023Joint bone spine
PubMed ↗Treatment patterns in patients with rheumatoid arthritis initiating a JAK inhibitor or a TNF inhibitor based on retail pharmacies drug-dispensing data
2025Rheumatology (Oxford, England)
PubMed ↗Do SMS/e-mail reminders increase influenza vaccination of rheumatoid arthritis patients under anti-TNF: a nested randomized controlled trial in the ART e-cohort
2024Annals of the rheumatic diseases
PubMed ↗EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease
2024Rheumatology (Oxford, England)
PubMed ↗Biomarker analysis from the phase 2b randomized placebo-controlled trial of riociguat in early diffuse cutaneous systemic sclerosis
2025Arthritis research & therapy
PubMed ↗The effect of hydroxychloroquine on activities of daily living and hand function in systemic sclerosis: results from an analysis of the EUSTAR cohort
2024RMD open
PubMed ↗Comorbidity burden on mortality in patients with systemic sclerosis
2025Orphanet journal of rare diseases
PubMed ↗Prevalence estimation of a rare disease with the French National Rare Disease Registry: example of TNF receptor associated periodic syndrome (TRAPS)
2024Joint bone spine
PubMed ↗Standardized reporting for systematic global evaluation of axial spondyloarthritis: An evidence-based and consensus-driven initiative
2024RMD open
PubMed ↗Frequency of irritable bowel syndrome in spondyloarthritis: a multicentric cross-sectional study and meta-analysis
2026Article
Club Rhumatismes et Inflammation guidelines for anti-interleukin-1 therapy: 2026 update
Joint Bone Spine
2026Article
Clinical characteristics and risk factors for calcinosis cutis in systemic sclerosis: insights from the EUSTAR database
Rheumatology
2026Article
Risk score for early mortality to stratify for intensive SSc therapy in the EUSTAR network: the RESIST score
Annals of the Rheumatic Diseases
2026Article
Prevalence of effective contraceptive use among patients with rheumatic diseases: a descriptive study
BMC Rheumatology
2026Article
Nailfold video capillaroscopy predicts severe progression at three years in systemic sclerosis: Results from SCLEROCAP study
Microvascular Research
2025Article
French recommendations for assessing and managing the risk of cancer before the initiation of targeted therapies for chronic rheumatic inflammatory diseases
Joint Bone Spine
2025Article
Maintenance of Remission After Tocilizumab Withdrawal in Patients With Glucocorticoid‐Dependent Polymyalgia Rheumatica
Arthritis & rheumatology
2025Article
Altered X-chromosome inactivation of the TLR7/8 locus and heterogeneity of pDCs in systemic sclerosis
Journal of Experimental Medicine
▶L’interprétation des anticorps antinucléaires, ou AAN
Société Française de Rhumatologie
▶Marie-Elise TRUCHETET & Estibaliz LAZARO - Retour d’expériences/cas cliniques
RESO Bordeaux
▶10 La recherche clinique et translationnelle sur la sclérodermie png
RESO Bordeaux
▶Actualités de la sclérodermie et recherche à Bordeaux, M-E TRUCHETET (3e journée RESO Bordeaux)
RESO Bordeaux
▶Médi'cas : la RHUMATOLOGIE
Orientation Carabins de Bordeaux Université de Bdx
lequotidiendumedecin.fr
Connectivites : « des nouvelles voies thérapeutiques originales » - lequotidiendumedecin.fr
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxPMFRlOVM5QWtTc2RSOW9NSzREODVZa3ZEZU9tWWwyQ0lBN1BpbDJSS01LX3dpY3BlN2t4UWFXSVFkR0F0RHhldnNfTWR6UzlRckctWEl5djhHYkgtUzN5cVhKdVZWOVl3NWRNby01VFBJLWtYSnE2clB1aXd3NzVLM1lXT2pMVzF3Q05SU19iaWYtaTZseHZxRVhRc2lGMnBHZ3cxdWhTeC1pMHpKdi1FTktmVFE1VnhPRU
hautegironde.fr
Blaye. Un éclairage sur une maladie rare - hautegironde.fr
<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxPSENnYzJXbXJTY1NGakNkM2Vxbi1vRUpqVUo2SVQ4eV9TYVp2MW5YNE5tZHRyMW1odXlYb1FRX2REbHp2T20tYnNiTXJ3am5KS1Y1VkY5c0k5ZjJOY052LVIxMXQtZFljZG9PZXF0ejVtal9BNlhiTkZXb3N6dUd5ZnlOaUdaVjZlVmc?oc=5" target="_blank">Blaye. Un éclairage sur une maladie rare
lequotidiendumedecin.fr
Vers de nouvelles pistes thérapeutiques dans la fibrose associée à la sclérodermie - lequotidiendumedecin.fr
<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxOTmdHN1ZndEtIc250YU9HQnJWLUxtbUVWYWFBUVMtR1VyMHI0cG9lQkJjejgzX0d0amY1RnlnVFdPSi1HV1A3bGg5QXRDcktrdlB0QUNpMGRnRzJ4LUVjX3lLNnI2NkNkbU0xYk5lLXprQzJRdmRwZkJIallUR2RwNVhmejFTeU9mb2xCckVCM1hJVTNQajNIeWVqMVFNZzVTeXViem93WUQ3RUF3azRqamJDaFNYbE5UZD
Encadrement de doctorants — signal d'activité universitaire.
2025Doctorant : Stefano Di donato
A reverse clinical translation platform for the molecular stratification of vascular progression in Systemic Sclerosis (SSc)
Bordeaux
2021Doctorant : Damien Leleu
Propriétés immunologiques et non immunologiques des microparticules au cours de la sclérodermie systémique
Bordeaux
Rhumatologues à proximité